Results are in for an open-label phase 2 clinical trial of interferon gamma (IFN-γ) treatment for Friedreich’s ataxia (FRDA) sponsored by Children’s Hospital of Philadelphia along with collaborators at the Friedreich’s Ataxia Research Alliance and Vidara Therapeutics Research Ltd. David Lynch, MD, PhD, served as the principal investigator. The…
News
Recent Posts
- Experimental FA gene therapy targeting brain and heart earns EU orphan status
- Grief and joy: Holding on to two realities with Friedreich’s ataxia
- The curious case of the future FA supposedly killed
- Gene editing approach for treating FA shows promise in lab cell models
- The cost of unreliable accessible transportation